ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Berberine Alleviates 1-Methyl-3-Nitro-1-Nitrosoguanidine- Induced Chronic Atrophic Gastritis in Rats.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alkaloids Mediate Multi-Level Modulation of Gastric Carcinogenesis: From Antibacterial and Anti-Inflammatory Actions to Antitumor Effects.International journal of molecular sciences · 2026Review
- Berberine and Berberine-Derived Compounds as Promising Weapons AgainstPharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Berberine (BBR), an isoquinoline alkaloid derived from Berberis plants, exhibits anti-inflammatory, anti-cancer, and antioxidant properties. This study explored the role of BBR in chronic atrophic gastritis (CAG). Materials and methods: The 1-methyl-3-nitro-1-nitrosoguanidine and an irregular diet were used to establish the CAG model. Chronic atrophic gastritis rats were administered BBR at different doses via gavage, and teprenone (TEP) served as the positive control drug. We monitored and measured changes in body weight and food intake, pepsin activity, and gastric acid levels in the rats. Hematoxylin and eosin staining was utilized to scan the pathological condition in the gastric mucosal tissue of rats, while enzyme-linked immunosorbent assay was utilized to analyze alterations in serum inflammatory factors and hormone levels. Western blot was employed to evaluate protein expression. Additionally, 16S rRNA was conducted to assess changes in the intestinal flora of CAG rats. Results: Berberine increased body weight and food intake, improved gastric atrophy, and enhanced pepsin activity and total acidity of gastric juice in CAG rats. BBR treatment led to decreased levels of inflammation factors and motilin, while gastrin and somatostatin levels were elevated in CAG rats. Additionally, BBR inhibited the NF-κB and MAPK pathway in these rats. Berberine treatment also regulated the composition and abundance of intestinal flora. These microbiome alterations suggest a possible role in modulating gut inflammation associated with CAG. Conclusion: Berberine may alleviate CAG injury by reducing inflammation and regulating intestinal flora, which may be closely associated with the NF-κB and MAPK pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.